These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30499738)

  • 1. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
    Montoro J; Pomares H; Villacampa G; Merchán B; Molero A; Alonso E; Gallur L; Grau J; Salamero O; Roldán E; Saumell S; Ortega M; Sureda A; Bosch F; Arnan M; Valcárcel D
    Leuk Lymphoma; 2019 Jun; 60(6):1522-1527. PubMed ID: 30499738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
    van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
    Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
    Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
    Gu S; Xia J; Tian Y; Zi J; Ge Z
    BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
    Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
    Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
    Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
    Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
    Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
    Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
    de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
    Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
    Mishra A; Corrales-Yepez M; Ali NA; Kharfan-Dabaja M; Padron E; Zhang L; Epling-Burnette PK; Pinilla-Ibarz J; Lancet JE; List AF; Komrokji RS
    Am J Hematol; 2013 Jul; 88(7):566-70. PubMed ID: 23605934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
    Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R
    Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.
    Yahng SA; Jeon YW; Yoon JH; Shin SH; Lee SE; Choi YS; Kim DY; Lee JH; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Lee JW; Lee KH; Min WS; Lee JH; Kim YJ
    Bone Marrow Transplant; 2017 Apr; 52(4):522-531. PubMed ID: 27892952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
    Zeidan AM; Sekeres MA; Wang XF; Al Ali N; Garcia-Manero G; Steensma DP; Roboz G; Barnard J; Padron E; DeZern A; Maciejewski JP; List AF; Komrokji RS;
    Am J Hematol; 2015 Nov; 90(11):1036-40. PubMed ID: 26284571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
    Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
    Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
    Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
    Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
    Lee JH; Kim YJ; Sohn SK; Yoon SS; Kim H; Cheong JW; Lee WS; Lee GW; Lim SN; Kim MK; Lee HS; Kim HJ;
    Leuk Res; 2017 Sep; 60():135-144. PubMed ID: 28826063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.